- Home
- MHUA vs BOLT Comparison
MHUA vs BOLT Comparison
Compare MHUA & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHUA | BOLT |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 11.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MHUA | BOLT |
|---|---|---|
| Price | $12.15 | $5.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 8.2K | ★ 33.3K |
| Earning Date | 12-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 28.96 | N/A |
| Revenue | ★ $89,547,563.00 | $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.26 | $4.41 |
| 52 Week High | $67.70 | $13.00 |
Technical Indicators
Market Signals| Indicator | MHUA | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 96.45 | 50.36 |
| Support Level | $0.13 | $4.66 |
| Resistance Level | $12.40 | $5.14 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | 1.41 | 0.06 |
| Stochastic Oscillator | 83.57 | 90.41 |
Price Performance
Historical ComparisonAbout MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.